U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951060) titled 'LP-184 for Advanced or Metastatic Urothelial Carcinoma Selected by PTGR1 Expression and DNA Repair Deficiency' on Nov. 03.
Brief Summary: This study investigates the safety and potential antitumor activity of LP-184 in patients with advanced or metastatic urothelial carcinoma.
LP-184 is an investigational anticancer drug designed to damage the DNA of cancer cells. Certain cancer cells may be particularly sensitive to LP-184 if they have impaired DNA repair mechanisms and express a protein called PTGR1, which is involved in activating the drug.
The study aims to investigate whether LP-184 can be safely administered and whether it c...